Compare
Definium Therapeutics, Inc. vs Jushi Holdings Inc. vs USANA Health Sciences Inc vs Ascend Wellness Holdings, Inc.
| Latest fiscal year | Definium Therapeutics, Inc. DFTX | Jushi Holdings Inc. JUSH | USANA Health Sciences Inc USNA | Ascend Wellness Holdings, Inc. AAWH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-01-03 | 2025-12-31 |
| Revenue | n/a | $262.91M | $925.26M | $500.58M |
| Revenue growth (YoY) | n/a | +2.1% | +8.3% | -10.9% |
| Gross margin | n/a | 43.4% | 78.3% | 33.9% |
| Operating margin | n/a | 1.8% | 4.0% | -3.4% |
| Net margin | n/a | -26.1% | 1.2% | -23.6% |
| Net income | -$183.79M | -$68.59M | $10.76M | -$118.19M |
| EPS (Diluted) | -$2.06 | -$0.35 | $0.58 | -$0.58 |
| Operating cash flow | -$131.56M | $17.73M | $22.35M | $38.05M |
| Free cash flow | n/a | $1.64M | $8.53M | $12.04M |
| Cash & equivalents | $257.84M | $24.05M | $158.38M | $85.68M |
| Total assets | $440.10M | $422.34M | $742.91M | $907.93M |
| Total liabilities | $107.77M | $537.69M | $156.64M | $954.55M |
| Shareholders' equity | $332.33M | -$115.34M | $533.10M | -$46.62M |
| Return on year-end equity | -55.3% | n/a | 2.0% | n/a |
| Shares outstanding | 98.78M | n/a | 18.28M | 202.22M |
Revenue, most recent five fiscal years
| Fiscal year | Definium Therapeutics, Inc. | Jushi Holdings Inc. | USANA Health Sciences Inc | Ascend Wellness Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $262.91M Ended 2025-12-31 | $925.26M Ended 2026-01-03 | $500.58M Ended 2025-12-31 |
| 1 year earlier | n/a | $257.52M Ended 2024-12-31 | $854.50M Ended 2024-12-28 | $561.60M Ended 2024-12-31 |
| 2 years earlier | n/a | $269.44M Ended 2023-12-31 | $921.01M Ended 2023-12-30 | $518.59M Ended 2023-12-31 |
| 3 years earlier | n/a | $284.28M Ended 2022-12-31 | $998.60M Ended 2022-12-31 | $405.93M Ended 2022-12-31 |
| 4 years earlier | n/a | $209.29M Ended 2021-12-31 | $1.19B Ended 2022-01-01 | $332.38M Ended 2021-12-31 |